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Abstract
Background: Major adverse cardiac and cerebrovascular event (MACCE) is one of most common complications of
hemodialysis patients. Heart rate variability (HRV) is the predictor of death in heart disease patients. However, there
are no studies on the role of HRV in hemodialysis patients.
Methods: From September 2009 to March 2011, 24-h electrocardiography was performed in 101 hemodialysis
patients. Standard deviation of sequential 5-minute N-N interval means (SDANN) and standard deviation of the N-N
interval (SDNN) was examined by a 24-h ECG analysis. Patients were observed prospectively. The primary endpoints
were incidence of MACCE and MACCE-free survival.
Results: We studied 90 hemodialysis patients (64 males, 63.4 ± 11.8 years old). During a follow-up period of 32.0 ±
11.7 months, 33 patients developed MACCE. 24-h ECG showed mean SDNN 93.4 ± 33.4 ms and mean SDANN 83.2
± 31.3 ms. MACCE group showed significantly lower SDNN and SDANN than event-free group. In Kaplan-Meier
analysis higher SDNN and SDANN group showed significantly higher event-free survival rate than lower group.
Using a Cox proportional hazards model, SDNN was independent prognostic factor while SDANN or diabetic status
was not significant. In diabetic cases, there were no differences in any factors for the incidence of MACCE between
higher SDNN, SDANN groups and lower groups. On the other hand in non-diabetic cases, lower SDNN or SDANN
group developed significantly higher MACCE than higher groups.
Conclusion: Measurement of HRV by Holter ECG is useful to predict MACCE in hemodialysis patients, especially
non-diabetic group.
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Background
Patients on hemodialysis frequently have major adverse car-
diac and cerebrovascular events (MACCE) which some-
times lead them to death [1, 2] and prediction and
prevention of MACCE are important for them. Numerous
factors have been reported to induce MACCE in
hemodialysis patients. Chronic overhydration status in
hemodialysis patients may induce structural or functional
disorders in myocardium, leading to arrhythmia. Electrolyte
imbalance and autonomic nerve disorder, sometimes ob-
served in hemodialysis patients, may cause cardiac sudden
death. Oxidative stress, inflammation and abnormal cal-
cium or phosphate metabolism, which are specific to
hemodialysis patients, may play some roles in atheroscler-
osis of coronary artery [3–5]. Hypertension, frequently
found in hemodialysis patients, is reported to be the most
important factor to cerebrovascular disorders [6]. Although
detection of high risk group in hemodialysis patients who
would develop MACCE is an important issue, there are no
reports on appropriate prognostic biomarkers available for
MACCE in hemodialysis patients [7, 8]. Here we propose
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the usefulness of Holter electrocardiogram (ECG) to predict
MACCE in hemodialysis patients.
Holter ECG, conducted over a 24-h period, is widely
used as non-invasive measures for the detection of car-
diac arrhythmia which is not found in usual ECG. Holter
ECG can also evaluate heartbeat change, such as heart
rate variability (HRV), by measuring palmic fluctuation.
HRV is an index of autonomic activity and includes the
standard deviation of the N-N interval (SDNN) and
standard deviation of sequential 5-minute N-N interval
means (SDANN). SDNN estimates the standard devi-
ation of the N-N intervals over 24 h, while SDANN re-
flects the standard deviation of the mean N-N intervals
calculated in 5-min segments over 24-h. The N-N inter-
val shows the R-R interval between consecutive QRS
complex peaks during normal sinus rhythm. Larger fluc-
tuation in the R-R intervals, thus higher HRV, can be
found at rest in healthy individuals since heart beats can
be physiologically changed by the influence of sympa-
thetic and parasympathetic function according to circa-
dian rhythm. On the other hand, R-R intervals become
relatively stable and lower HRV is detected under strong
stress or autonomic nerve dysfunction.
HRV is greatly influenced by age and heart rate [9].
Furthermore previous study suggested that patients with
diabetes or hypertrophic cardiomyopathy showed de-
creased HRV [9–13]. It is also reported that the cardiac
patients with decreased HRV showed poor prognosis
[14, 15]. Lower HRV is reported to be associated with
sudden cardiac death from cardiac arrhythmia or post
myocardial infarction [16, 17]. In hemodialysis patients
HRV is reduced and decreased HRV is observed already
at the stage of chronic kidney failure prior to initiation
of dialysis [18, 19]. However there are no studies on the
role of HRV in the prognosis of hemodialysis patients.
In this study, we examined the association between HRV
and MACCE in hemodialysis patients to determine
prognostic factors and the influence of diabetic status on
HRV was also studied.
Methods
From September 2009 to March 2011, 24-h ECG was
performed in 101 patients on hemodialysis treated at
Osaka General Medical Center, Yuseikai Clinic and
Nagahara Hospital. Holter monitor (FM8800; Fukuda
Denshi Co Ltd, Tokyo, Japan), was attached to the
patients before the start of hemodialysis and data were
collected on 2 channels for 24 h. SDANN and SDNN as
an index of HRV were examined as well as the check of
atrial and ventricular arrhythmias by a 24-h electrocar-
diographic analysis using an SCM-6600 System (Fukuda
Denshi Co, Ltd, Tokyo, Japan).
Clinical data were utilized, including age, gender, body
mass index (BMI), duration of hemodialysis, medication
of antihypertensives, blood pressure, and fluid removal
volume. Biochemical analysis was performed before and
after hemodialysis, including serum sodium, potassium,
calcium, chloride, blood urea nitrogen, creatinine, albu-
min, and hemoglobin levels. All the patients did not
undergo hemodiafiltration and acetate free biofiltration,
but underwent hemodialysis with bicarbonate dialysate
and high-flux polysulfone, ethylene vinyl alcohol, and
polyethersulfone membrane with a surface area ranging
from 0.8 to 2.5 m2.
The hemodialysis patients were examined prospect-
ively for observational study until December 31, 2013.
The primary endpoints were incidence of MACCE and
MECCE-free survival. The patients were divided into
low-level (SDNN 45 cases, SDANN 44 cases) and high-
level groups (SDNN 45 cases, SDANN 46 cases) respect-
ively according to the median value for cutoff line, and
all-cause death and MACCE during the observation
period were checked.
Subjective 101 patients included 36 females and 65
males. One patient with chronic atrial fibrillation was also
excluded because HRV could not be obtained. Ten pa-
tients who died of cancer or complication after renal
transplantation during the observation period were ex-
cluded from the study. Therefore 90 patients (26 females
and 64 males) were studied during the observation period.
Informed consent was obtained from all study partici-
pants in accordance with the Helsinki Declaration, and
the study was approved by the ethical review boards of
the treating institutions. Data are shown as mean ±
standard deviation (SD) and statistical analysis was con-
ducted using IBM SPSS software (IBM SPSS version
11.0; IBM, Chicago, Illinois, USA). Continuous variables
were compared using a paired t-test, and data of the
nominal scale were analyzed by the χ2 test. Event-free
survival data are depicted in a Kaplan-Meier analysis.
Univariate and multivariate analyses were conducted to
determine the risk factors. Significance level for the pri-
mary endpoint was set at 5%.
Results
Ninety patients (26 females and 64 males) were studied
during the observation period; baseline clinical charac-
teristics and biochemical data are shown in Table 1.
Mean age was 63.4 ± 11.8 years, with mean 68.4 ±
73.4 months duration on hemodialysis. For primary
cause of hemodialysis, 44 patients (48.9%) had diabetic
nephropathy, 30 patients (33.3%) had chronic glomer-
ulonephritis, and 16 (17.8%) had unknown or other dis-
eases. Mean BMI was 21.6 ± 3.2 kg/m2. Forty-four
patients were treated with angiotensin receptor blockers,
39 with beta blockers, 48 with calcium channel blockers,
and 4 with angiotensin-converting enzyme inhibitors.
The mean volume of water removed during hemodialysis
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of 3–4 h was 2.2 ± 1.2 kg and the mean systolic/diastolic
blood pressure prior to the hemodialysis was 153.7 ±
19.1 mmHg/122.3 ± 18.2 mmHg. Blood biochemistry
data before hemodialysis were as follows: hemoglobin
(Hb), 10.1 ± 1.1 g/dl; albumin, 3.9 ± 0.5 g/dl; serum so-
dium, 138.3 ± 3.5 mEq/l; and serum potassium, 4.3 ±
0.7 mEq/l.
Twenty-four hour ECG shows mean N-N 805.4 ±
107.2 ms; mean SDNN 93.4 ± 33.4 ms (median 91.5) and
mean SDANN, 83.2 ± 31.3 ms (median 79.3). The pa-
tients were divided into low-level (SDNN 45 cases,
SDANN 44 cases) and high-level groups (SDNN 45
cases, SDANN 46 cases) respectively according to the
median value for cutoff line, and all-cause death and
MACCE during the observation period were checked.
During 24-h Holter ECG 48 patients developed prema-
ture ventricular contraction (PVC); 41 cases with low-
risk PVCs and 7 cases with high-risk ones such as coup-
let PVC and PVC short run.
For the mean observation period of 32.0 ± 11.7 months
(range: 1–49 months), 33 patients (36.7%) developed
MACCE. Thirteen patients (39.4%) died during the ob-
servation period; cause of death is heart failure in 10
patients, arrhythmia in 2 patients and cerebral bleeding
in 1 patient. Seventeen (51.4%) and 4 (12.1%) patients
developed cardiovascular and cerebrovascular complica-
tions respectively.
There were no statistical differences in age,
hemodialysis duration, BMI, fluid removal volume, Hb,
albumin, electrolytes and administration of antihyperten-
sives between the MACCE group and non-MACCE
group. The systolic blood pressure change between pre-
and post-hemodialysis was higher in event group than
event-free group (35.3+/−19.9 vs 33.0+/−18.6 mmHg; p
< 0.05). Event group included more diabetes mellitus
(DM) patients than event-free group (66.7 vs 22.2%; p <
0.01). Event group showed much lower SDNN and
SDANN than event-free group (SDNN 78.3+/−31.2 vs
102.1+/−31.7 ms; p = 0.00, SDANN 70.7+/−30.7 vs 90.2
+/−29.5 ms; p = 0.00) (Table 2).
When we compare low and high SDNN groups in the
clinical and biochemical data, there were no statistical
differences in age, hemodialysis duration, BMI, adminis-
tration of antihypertensives, Hb, albumin, fluid removal,
blood pressure and blood pressure change except DM;
29 DM cases (55.1%) in 49 low SDNN patients vs 15
DM cases (36.6%) in 41 high SDNN ones ( p < 0.05).
However, incidence of MACCE in low SDNN group was
Table 1 Characteristics of the study subjects
All patients (n = 90)
Age (year) 63.4 ± 11.8
Gender (f/m) 26:64
Duration of HD (months) 68.4 ± 73.4 (1–328)
Primary Cause of HD, n (%)
Diabetic Nephropathy 44 (48.9%)
Chronic glomerulonephritics 30 (33.3%)
Unknown or others 16 (17.8%)
Body Mass Index (kg/m2) 21.6 ± 3.2
PVC,n (%) 48 (53.3%)
Medication, n (%)
ARB 54 (60.0%)
Beta blockers 39 (43.3%)
48 (53.3%) Ca channel blockers
ACE 4 (4.4%)
Hemoglobin (g/dl) 10.1 ± 1.1
Albumin (g/dl) 3.9 ± 0.5
pre/postHD Na (mEq/l) 138.3 ± 3.5/139.9 ± 2.1
pre/postHD K (mEq/l) 4.3 ± 0.7/3.3 ± 0.4
pre/postHD Ca (mg/dl) 9.2 ± 1.3/9.5 ± 1.0
Fluid removal (kg) 2.2 ± 1.2
Pre/post HD systolic blood pressure (mmHg) 153.7 ± 19.1/122.3 ± 18.2
Pre/post HD diastolic blood pressure (mmHg) 70.4 ± 14.3/73.1 ± 16.6
PVC premature ventricular contraction, ARB angiotensin receptor blocker, Ca
channel blockers calciumchannel blockers, ACE angiotensin-converting
enzyme inhibitor






Age (year) 63.7 ± 11.9 63.3 ± 11.8 0.87
HD duration (mounts) 64.7 ± 68.9 70.9 ± 76.1 0.69
DM (n,%) 22 (66.7) 11 (33.3) 0.01
BMI (kg/m2) 21.3 ± 3.5 21.8 ± 3.0 0.49
PVC (n,%) 26 (78.8) 7 (21.2) 0.01
Hb (g/dl) 10.4 ± 1.0 10.5 ± 1.2 0.78
Alb (g/dl) 3.8 ± 0.4 3.9 ± 0.5 0.50
Fluid removal (kg) 2.3 ± 1.3 2.2 ± 1.2 0.51
ARB (n,%) 16 (48.5) 23 (40.4) 0.45
β blocker (n,%) 19 (57.6) 35 (61.4) 0.72
Ca channel blockers (n,%) 17 (51.5) 31 (54.3) 0.63
Na (mEq/l) 139 ± 3.4 138.2 ± 3.5 0.30
K (mEq/l) 4.4 ± 0.8 4.2 ± 0.7 0.47
Ca (mEq/l) 9.1 ± 1.3 9.3 ± 1.3 0.49
SDNN (ms) 78.3 ± 31.2 102.1 ± 31.7 <0.001
SDANN (ms) 70.7 ± 30.7 90.2 ± 29.5 <0.001
⊿Sys blood pressure (mmHg) 35.3 ± 19.9 33.0 ± 18.6 0.05
⊿Dia blood pressure (mmHg) 14.5 ± 7.8 13.2 ± 8.1 0.47
DM diabetes mellitus, BMI body mass index, PVC premature ventricular
contraction, Hb hemoglobin, Alb albumin, ARB angiotensin receptor blocker,
Ca channel blockers calciumchannel blockers, SDNN standard deviation of the
NN interval, SDANN standard deviation of sequential five-minute N-N
interval means
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55.1% (27/49), much higher than that in high SDNN
group, 14.6% (6/41) (p < 0.01). Also low and high
SDANN groups were compared in the similar ways.
There were no statistical differences in any data includ-
ing DM. However, low SDANN group had much higher
incidence of MACCE than high SDANN group (47.4%
(27/57) vs 18.2% (6/33); p = 0.01). Low SDNN group de-
veloped PVC more frequently than high SDNN group
during 24-h ECG (p < 0.05) as well as more frequent in-
cidence of PVC in low SDANN group (p < 0.03).
In Kaplan-Meier analysis higher SDNN group showed
much higher event-free survival rate than lower SDNN
group (Log rank, p = 0.00) as well as higher SDANN
group showed significantly higher survival rate (Log
rank, p = 0.01) (Fig. 1). In the longer follow-up time the
difference of event-free survival between SDNN higher
and lower groups, as well as SDANN higher and lower
groups, seems to be increased. In the analysis using a
Cox proportional hazards model, SDNN was determined
to be an independent prognostic factor (p = 0.02; hazard
ratio: 0.57) while SDANN or diabetic status was not sig-
nificant in multivariate analysis (Table 3).
Predictive factors for MACCE are analyzed separately
in both diabetic and non-diabetic patients. In diabetic 44
cases 22 patients (50%) developed MACCE and there
were no significant differences in any factors including
SDNN and SDANN for the incidence of MACCE. On
the other hand 11 patients (23.9%) developed MACCE
in non-diabetic 46 cases, much less rate than diabetic
group. There were no significant differences in age,
hemodialysis duration, hemoglobin level, albumin level,
or BMI for MACCE. However, lower SDNN or SDANN
group developed significantly higher MACCE than
higher groups (p = 0.00 or p = 0.04, Table 4).
Discussion
Although the prognosis of the hemodialysis patients has
been improved, they still have higher risk for MACCE
and earlier detection of MACCE is important in clinical
practice [20]. In hemodialysis facility anemia, nutrition
and bone metabolic markers are usually checked by the
laboratory examination, but it is difficult for the predic-
tion of MACCE from those laboratory data. Radiography
like coronary angio-CT or ultrasonography is not usually
so convenient in hemodialysis facility and sufficient
examination for early detection is not performed. In this
study we investigate the possibility of prediction of prog-
nosis of the hemodialysis patients by Holter ECG, easy
and non-invasive measures available in usual
hemodialysis facility.
HRV obtained by Holter ECG reflects the balance of
sympathetic and parasympathetic nervous function [9, 10].
Decreased HRV defined by SDNN or SDANN, which shows
no difference in heartbeats between in the daytime and at
night, is considered as a state of sympathetic hyperactivity.
Activated condition of sympathetic nerve function is known
to induce lethal arrhythmia leading to sudden death [21].
An earlier study reported that prognosis of patients with
heart failure or ischemic heart disease was intimately linked
to HRV [22, 23].
In this study the incidence of MACCE was signifi-
cantly correlated with diabetic status, low SDNN, low
SDANN and high blood pressure change during
hemodialysis. Our result is consistent with the previous
reports in which the hemodialysis patients from diabetic
nephropathy have higher risk for MACCE [24]. Our re-
sults that the patients with MACCE showed significantly
lower SDNN and SDANN were noteworthy because de-
creased HRV might reflect high cardiac overload
Fig. 1 Event-free survival of hemodialysis patients with higher and lower heart rate variability. captions: a SDNN higher group showed
significantly higher MACCE-free survival than SDNN lower group. b SDANN higher group showed significantly higher MACCE-free survival than
SDANN lower group
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resulting in MACCE. Higher blood pressure change dur-
ing hemodialysis significantly associated with MACCE
means that cardiac function was so poor that decreased
circulating blood volume due to hemodialysis may de-
velop higher blood pressure change.
In this study SDNN and SDANN low-level groups had
higher incidence of MACCE and worse outcome than
the high-level groups and also SDNN and SDANN lower
groups showed significantly lower event-free survival in
Kaplan-Meier analysis than higher groups. Furthermore
SDNN was an independent prognostic factor in COX-
hazard analysis while SDANN was not. SDNN estimates
the standard deviation of the mean values of NN interval
for 24 h and reflects an HRV change over the long-term
more strongly compared with SDANN which indicates
the standard deviation of the mean N-N intervals calcu-
lated in 5-min segments over 24-h. Therefore, SDNN is
a more sensitive predictor of prognosis than SDANN.
These results suggest that body fluid volume should be
strictly regulated by hemodialysis and that early detec-
tion of cardiovascular complications should be recom-
mended in the hemodialysis patients with HRV decrease
since those patients were at high risk for MACCE. When
we analyzed incidence of PVC, low SDNN group devel-
oped PVC more frequently as well as low SDANN
group. PVC has been reported to be associated with age,
sympathetic nerve imbalance and cardiac dysfunction.
Furthermore, the patients with PVC had more incidence
of MACCE (p < 0.01), suggesting low SDNN and
SDANN might result ventricular arryhtmia and that
could be predictable factors for MACCE .
In the current study HRV was not correlated with age
or dialysis history. Our result might suggest that some
patients showed activated sympathetic function resulting
in poor prognosis already at the early stage of chronic
renal failure. Generally long term dialysis is supposed to
induce MACCE. However, there are high risk group of
hemodialysis patients even at the initiation stage of
hemodialysis with the increased older population or dia-
betic status for hemodialysis. As previous study showed
HRV are already decreased at the stage of advanced
chronic kidney disease prior to initiation of dialysis, the
measurement of HRV at the initiation of hemodialysis
would be useful for the detection of high risk group of
MACCE [18]. In this study there were no differences in
SDNN and SDANN between no medications and medi-
cations with of beta blocker or calcium blocker. Previous
study reported medication with calcium blocker induced
activation of parasympathetic function, resulting in
short-term HRV such as mean R-R intervals calculated
in 5-min segments [25]. In this study we tested only
long-term HRV and so no differences were observed.
The hemodialysis patients with diabetic nephropathy
as primary disease have been reported to show poor
prognosis. In this study low SDNN or SDANN group
showed similar incidence of MACCE to high SDNN or
SDANN group in the diabetic patients, whereas low
SDDN or SDANN group demonstrated significantly
higher incidence of MACCE than high group in non-
Table 3 COX regression model for MACCE
Univariate analysis Multivariate analysis
p value Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
Age 0.78 1.0 (0.98–1.02)
HD duration 0.84 1.0 (0.99–1.00)
DM 0.02 1.6 (1.09–2.56) 0.06 1.5 (0.9–2.4)
SDNN 0.01 0.5 (0.37–0.87) 0.02 0.57 (0.36–0.89)
SDANN 0.12 0.7 (0.48–1.14)
PVC 0.06 2.1 (0.88–2.73)
ARB 1.00 1 (0.50–1.99)
β blocker 0.54 0.9 (0.57‐1.34)
Hb 0.90 1.0 (0.82–1.20)
Alb 0.11 1.5 (0.91–2.46)




DM diabetes mellitus, SDNN standard deviation of the NN interval, SDANN
standard deviation of sequential five-minute N-N interval means, PVC premature
ventricular contraction, ARB angiotensin receptor blocker, Hb hemoglobin,
Alb albumin
Table 4 MACCE-correlated factors in diabetic and non-diabetic subjects
DM (n = 44) Non-DM (n = 46)
With MACCE (n = 22) Without MACCE (n = 22) p value With MACCE (n = 11) Without MACCE (n = 35) p value
Age (year) 61.9 ± 12.8 63.1 ± 12.6 0.75 67.4 ± 9.6 63.4 ± 11.4 0.41
HD duration (months) 46.0 ± 11.6 46.6 ± 10.5 0.97 102.1 ± 81.8 86.3 ± 86.1 0.83
Alb (g/dl) 3.9 ± 0.4 4.0 ± 0.5 0.60 3.7 ± 0.4 3.9 ± 0.5 0.86
Hb (g/dl) 10.5 ± 1.1 10.7 ± 1.0 0.61 10.3 ± 0.8 10.4 ± 1.3 0.81
Fluid removal (kg) 2.4 ± 1.5 2.1 ± 1.1 0.41 2.2 ± 1.1 2.2 ± 1.2 0.91
SDNN (Low,n%) 16 (72.7%) 11 (50.0%) 0.12 7 (63.6%) 11 (31.4%) 0.05
SDANN (Low,n%) 16 (72.7%) 13 (59.1%) 0.34 8 (72.7%) 9 (25.7%) 0.01
Alb albumin, Hb hemoglobin, SDNN standard deviation of the NN interval, SDANN standard deviation of sequential five-minute N-N interval means
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diabetic patients. Earlier research has shown that dia-
betic condition itself is a strong risk factor for MACCE
and the contribution of HRV might be relatively low. On
the other hand, low SDNN or SDANN patients show
higher incidence for MACCE in non-diabetic patients in
our study, suggesting low HRV might be a strong risk
factor for prognosis in non-diabetic hemodialysis
patients.
There are several limitations to our study. First, the
sample size of 90 patients was small. Secondly cardiac
function by echocardiography was not evaluated since
echocardiogram was not equipped in one clinic and the
association of SDNN and SDANN with cardiac function
such as left ventricular end-diastolic dimension and left
ventricular ejection fraction. Thus the relationship be-
tween MACCE and cardiac function was not discussed
sufficiently.
Conclusion
Measurement of HRV by Holter ECG is useful to predict
MACCE in hemodialysis patients, especially non-
diabetic group.
Abbreviation
BMI: Body mass index; ECG: Electrocardiogram; Hb: Hemoglobin; HRV: Heart
rate variability; MACCE: Major adverse cardiac and cerebrovascular events;
PVC: Premature ventricular contraction; SDANN: Standard deviation of
sequential 5-minute N-N interval means; SDNN: Standard deviation of the
N-N interval
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